Therapeutic benefit of bone marrow stromal cells administered 1 month after XXXX .

@entity9018 @entity64 @entity9017 @entity2500 @entity4613 @entity35 @entity19744
Bone marrow stromal cells (BMSCs) facilitate functional recovery in @entity35 after @entity64 when administered acutely (1 day) or subacutely (7 days). In this study, we postponed the time of cell transplantation to 1 month after @entity64 . Female retired breeder @entity35 were subjected to 2 h of @entity2500 ( @entity2500 ). Male BMSCs (3 x 10(6)) or @entity4613 -buffered saline were administered intravenously, and the animals were killed 3 months later. An additional population of nontreated @entity35 was killed at 1 month after @entity2500 . Significant recovery of behavior was found in BMSC-treated @entity35 beginning at 1 month after cell injection in the modified neurologic severity score test and the adhesive-removal test compared with control animals (P<0.05). In situ hybridization showed that BMSCs survived and preferentially localized to the ipsilateral hemisphere. Double staining revealed that approximately 13% and 6% Y-chromosome-positive cells expressed the astrocyte marker, glial fibrillary acidic protein, and the neuronal marker, @entity19744 , respectively. In addition, BMSC treatment reduced scar thickness, and increased the number of proliferating cells and oligodendrocyte precursor cells along the subventricular zone in the ipsilateral hemisphere. Expression of the chemokine @entity9017 ( @entity9017 ) was significantly increased along the ischemic boundary zone compared with the corresponding areas in the contralateral hemisphere at 1 month and 4 months (P<0.01) after @entity64 . The @entity9018 , @entity9018 ( @entity9018 ), was expressed in BMSCs both in vitro and in vivo. Our data show that the time window of BMSC therapy is at least 1 month after @entity64 ; the interaction of @entity9017 / @entity9018 may contribute to the trafficking of transplanted BMSCs.
